Efavirenz in pregnancy

摘要: Clinical guidelines from the National Department of Health (DoH), South Africa, for prevention mother-tochild transmission (PMTCT), revised in 2010, recommend that HIV-positive pregnant women with a CD4 count 350 cells/μl or less commence lifelong antiretroviral therapy (ART).¹ DoH guidance initiating ART pregnancy public sector – on which overwhelming majority Africans rely their care recommends they receive nevirapine tenofovir and lamivudine emtricitabine at any stage gestation. In cases where woman is already receiving an efavirenz-based regimen, it recommended this should be substituted if she still first trimester pregnancy. Efavirenz therefore contraindicated time during pregnancy; those drug, only switched trimester. The concern about use efavirenz dates back to preclinical studies. It primate data turn has strongest US Food Drug Administration (FDA) category most scrutiny pregnancy.² drug also conflicting recommendations, both product labelling. This article summary what we know (and do not know) using We argue reconsideration risk benefits evidence, informed African guidance, warranted.